Literature DB >> 6189586

Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.

L H Matherly, D W Fry, I D Goldman.   

Abstract

5-Formyltetrahydrofolate was found to reverse the binding of methotrexate to dihydrofolate reductase in the Ehrlich ascites tumor in vitro. When cells pretreated with methotrexate were resuspended in methotrexate-free buffer containing 5-formyltetrahydrofolate (or 5-methyltetrahydrofolate), net dissociation of the antifolate from the enzyme was observed. Methotrexate associated with the enzyme under these conditions was below the enzyme binding capacity. However, glucose or azide increased the fraction of dihydrofolate reductase associated with methotrexate and abolished the effect of tetrahydrofolates on this intracellular component. Addition of 5-fluoro-2'-deoxyuridine had no effect on this response to the reduced folate, thereby precluding a direct role for the thymidylate synthase-dependent generation of dihydrofolate in this dissociation of methotrexate from dihydrofolate reductase. Enzyme-bound methotrexate could also be reduced by exposure to 5-formyltetrahydrofolate prior to uptake and efflux of free methotrexate. When cells were incubated under conditions which favored formation of methotrexate polyglutamate derivatives, subsequent treatment with 5-formyltetrahydrofolate had no effect on the binding of the conjugated antifolate to dihydrofolate reductase. These findings support a role for dihydrofolate reductase as a locus for competitive binding interactions between reduced folates and methotrexate that may be a basis for the ability of 5-formyltetrahydrofolate to prevent the biochemical effects of this antifolate. These data suggest that the presence of methotrexate polyglutamate derivatives and cellular energy metabolism may be critical determinants of the responsiveness of methotrexate-treated cells to reduced folates and may play important roles in the selectivity of 5-formyltetrahydrofolate rescue.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189586

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.

Authors:  Michele Visentin; Ersin Selcuk Unal; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-29       Impact factor: 3.333

2.  Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Authors:  J S Lee; W K Murphy; M H Shirinian; A Pang; W K Hong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

4.  Quantitative aspects of the selective killing of transformed cells by methotrexate in the presence of leucovorin.

Authors:  M Chow; H Rubin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

5.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

Review 6.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

7.  N5-Formyltetrahydrofolate counteracts methotrexate toxicity in tobacco cell culture.

Authors:  G L Creason; R A Gonzales
Journal:  Plant Cell Rep       Date:  1988-05       Impact factor: 4.570

8.  Protection of cells from methotrexate toxicity by 7-hydroxymethotrexate.

Authors:  J M Gaukroger; L Wilson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.